Tina Bhutani

Dec 11, 2024 | jamanetwork.com | Andrew Alexis |Amy J. McMichael |Tina Bhutani

Key PointsQuestion  Can innovative clinical trial design overcome barriers to recruiting and retaining participants with psoriasis and skin of color? Findings  This quality improvement study found that the VISIBLE trial achieved broad diversity among its approximately 200 participants through self-identification of race and ethnicity and inclusion of all skin types.

Oct 4, 2024 | mdedge.com | April Armstrong |Robert Bissonnette |Raj Chovatiya |Tina Bhutani

Psoriasis is a chronic inflammatory disease affecting approximately 8 million adults in the United States and 2% of the global population.1,2 Psoriasis causes pain, itching, and disfigurement and is associated with a physical, psychological, and economic burden that substantially affects health-related quality of life.3-5 Setting treatment goals and treating to target are evidence-based approaches that have been successfully applied to several chronic diseases to improve patient outcomes,...

Apr 20, 2023 | social.cn1699.com | Tina Bhutani

Source/DisclosuresPublished by: Disclosures: The authors report no relevant financial disclosures. We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to HealioKey takeaways: Patients with psoriasis taking methotrexate are 2.8 times more likely to develop nonmelanoma skin cancer than those not taking the drug. Patients taking methotrexate should get regular body scans during treatment.

Apr 20, 2023 | nouvelles-du-monde.com | Tina Bhutani

Tina Bhutani, MD, MASBien que l’étude soit intéressante, elle ne montre qu’une association et non une causalité entre le méthotrexate et le cancer de la peau et il n’y a pas suffisamment de preuves pour modifier les directives de traitement clinique à l’heure actuelle. Cependant, la discussion ci-dessus est importante lorsque l’on envisage un traitement au méthotrexate.

Mar 29, 2023 | dovepress.com | Joy Jin |Riley Spencer |Vidhatha Reddy |Tina Bhutani

Back to Journals » Therapeutics and Clinical Risk Management » Volume 19 Authors Jin JQ , Spencer RK, Reddy V , Bhutani T, Liao W Received 29 March 2023 Accepted for publication 15 May 2023 Published 18 May 2023 Volume 2023:19 Pages 413—423 DOI https://doi.org/10.2147/TCRM.S388324 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Professor Garry Walsh Joy Q Jin,1,2 Riley K Spencer,2 Vidhatha Reddy,2 Tina Bhutani,2...